Indeed, FGFR2 inhibitors added to HER2-positive breast cancer cells after failure of treatment with the anti-HER2 drug lapatinib suggest a switch in cell addition to signalling inhibitors [101,217]. Here, FGFR2 is linked to breast carcinoma.